Feed GKOS
GK

Glaukos GKOS · NYSE

$177.03 +2.08% (+$3.60)

Market cap
$10.4B
Enterprise value
$10.4B
P/E
-
Forward P/E
-
PEG
-
P/S
17.0x
P/FCF
-
EV/EBITDA
-
ROIC
-9.6%
Gross margin
79.1%
Net margin
-30.7%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.70
Free float
96.0%

About the company

Glaukos Corporation is an American biotechnology company focused on the development and manufacture of innovative ophthalmic products. Founded in 1998, its headquarters are located in San Clemente, California. Glaukos specializes in the treatment of glaucoma and other eye diseases using new technologies, including implants and micro-surgical solutions. The company focuses on improving patients' quality of life through groundbreaking products and services that bring innovation to the field of ophthalmology.

Sector

Healthcare

Industry

Medical - Devices

CEO

Thomas William Burns

Employees

1,094

Headquarters

Aliso Viejo

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.